Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Reckitt Benckiser Group acquisition of Biofreeze
We are advising RB on the acquisition
Ayala Pharmaceuticals $25 million private placement
We advised the placement agent on the private placement of stock and warrants
InnoCare Pharma HK$3.04 billion share placement
We advised InnoCare Pharma in the placement of new shares
New Horizon Health HK$2.04 billion IPO
We advised New Horizon Health on its IPO and HKEX listing
Akeso HK$1.19 billion share placement
We advised the placing agent in the placement of new shares
Charles River Laboratories $875 million acquisition of Cognate
We advised Charles River on the acquisition of a cell and gene therapy contract development and manufacturing organization
Corvus Pharmaceuticals $34 million stock offering
We advised the underwriters on the equity offering
Biogen exchange offer
We advised the dealer managers on a debt exchange offer
Oak Street Health $600.5 million secondary offering
We advised the joint book-running managers on the equity offering
Signify Health $648.6 million IPO
We advised Signify Health on its IPO and NYSE listing